TY - JOUR
T1 - Delays Starting Postoperative Radiotherapy Among Head and Neck Cancer Patients
T2 - A Systematic Review and Meta-analysis
AU - Duckett, Kelsey A.
AU - Kassir, Mohamed Faisal
AU - Nguyen, Shaun A.
AU - Brennan, Emily A.
AU - Chera, Bhishamjit S.
AU - Sterba, Katherine R.
AU - Hughes Halbert, Chanita
AU - Hill, Elizabeth G.
AU - McCay, Jessica
AU - Puram, Sidharth V.
AU - Sandulache, Vlad C.
AU - Kahmke, Russel
AU - Ramadan, Salma
AU - Nussenbaum, Brian
AU - Alberg, Anthony J.
AU - Graboyes, Evan M.
N1 - Publisher Copyright:
© 2023 American Academy of Otolaryngology–Head and Neck Surgery Foundation.
PY - 2024/2
Y1 - 2024/2
N2 - Objective: Initiating postoperative radiotherapy (PORT) within 6 weeks (42 days) of surgery is the first and only Commission on Cancer (CoC) approved quality metric for head and neck squamous cell carcinoma (HNSCC). No study has systematically reviewed nor synthesized the literature to establish national benchmarks for delays in starting PORT. Data Sources: Following Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, we performed a systematic review of PubMed, Scopus, and CINAHL. Review Methods: Studies that described time-to-PORT or PORT delays in patients with HNSCC treated in the United States after 2003 were included. Meta-analysis of proportions and continuous measures was performed on nonoverlapping datasets to examine the pooled frequency of PORT delays and time-to-PORT. Results: Thirty-six studies were included in the systematic review and 14 in the meta-analysis. Most studies utilized single-institution (n = 17; 47.2%) or cancer registry (n = 16; 44.4%) data. Twenty-five studies (69.4%) defined PORT delay as >6 weeks after surgery (the definition utilized by the CoC and National Comprehensive Cancer Network Guidelines), whereas 4 (11.1%) defined PORT delay as a time interval other than >6 weeks, and 7 (19.4%) characterized time-to-PORT without defining delay. Meta-analysis revealed that 48.6% (95% confidence interval [CI], 41.4-55.9) of patients started PORT > 6 weeks after surgery. Median and mean time-to-PORT were 45.8 (95% CI, 42.4-51.4 days) and 47.4 days (95% CI, 43.4-51.4 days), respectively. Conclusion: Delays in initiating guideline-adherent PORT occur in approximately half of patients with HNSCC. These meta-analytic data can be used to set national benchmarks and assess progress in reducing delays.
AB - Objective: Initiating postoperative radiotherapy (PORT) within 6 weeks (42 days) of surgery is the first and only Commission on Cancer (CoC) approved quality metric for head and neck squamous cell carcinoma (HNSCC). No study has systematically reviewed nor synthesized the literature to establish national benchmarks for delays in starting PORT. Data Sources: Following Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, we performed a systematic review of PubMed, Scopus, and CINAHL. Review Methods: Studies that described time-to-PORT or PORT delays in patients with HNSCC treated in the United States after 2003 were included. Meta-analysis of proportions and continuous measures was performed on nonoverlapping datasets to examine the pooled frequency of PORT delays and time-to-PORT. Results: Thirty-six studies were included in the systematic review and 14 in the meta-analysis. Most studies utilized single-institution (n = 17; 47.2%) or cancer registry (n = 16; 44.4%) data. Twenty-five studies (69.4%) defined PORT delay as >6 weeks after surgery (the definition utilized by the CoC and National Comprehensive Cancer Network Guidelines), whereas 4 (11.1%) defined PORT delay as a time interval other than >6 weeks, and 7 (19.4%) characterized time-to-PORT without defining delay. Meta-analysis revealed that 48.6% (95% confidence interval [CI], 41.4-55.9) of patients started PORT > 6 weeks after surgery. Median and mean time-to-PORT were 45.8 (95% CI, 42.4-51.4 days) and 47.4 days (95% CI, 43.4-51.4 days), respectively. Conclusion: Delays in initiating guideline-adherent PORT occur in approximately half of patients with HNSCC. These meta-analytic data can be used to set national benchmarks and assess progress in reducing delays.
KW - Commission on Cancer
KW - National Comprehensive Cancer Network
KW - adjuvant therapy
KW - head and neck cancer
KW - quality
KW - radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=85171650714&partnerID=8YFLogxK
U2 - 10.1002/ohn.538
DO - 10.1002/ohn.538
M3 - Review article
C2 - 37731255
AN - SCOPUS:85171650714
SN - 0194-5998
VL - 170
SP - 320
EP - 334
JO - Otolaryngology - Head and Neck Surgery (United States)
JF - Otolaryngology - Head and Neck Surgery (United States)
IS - 2
ER -